BV 06
Alternative Names: BV-06Latest Information Update: 13 Sep 2023
Price :
$50 *
At a glance
- Originator Benovus Bio
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Laminin receptor modulators; Neoplasm antigen modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Aug 2016 Preclinical trials in Cancer in USA (Parenteral)